A PHASE 1B STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, AND CLINICAL ACTIVITY OF GS 9820 MONOTHERAPY AND COMBINATION THERAPY IN SUBJECTS WITH LYMPHOID MALIGNANCIES

Registry ID

GS-US-315-0102

Source registry

HEALTH_CANADA

Status

Pending

Phase

PHASE1

Study type

INTERVENTIONAL

Sponsor

GILEAD SCIENCES CANADA INC

Last update

2013-12-12

Conditions

• LYMPHOID MALIGNANCIES

Related clinical trials

• A PHASE 1, DOSE-ESCALATION/DOSE-EXPANSION STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMIC EFFECTS OF ORALLY ADMINISTERED CB-5083 IN SUBJECTS WITH LYMPHOID HEMATOLOGICAL MALIGNANCIES
• A PHASE I/II STUDY OF PEMBROLIZUMAB (MK-3475) IN CHILDREN WITH ADVANCED MELANOMA OR A PD-L1 POSITIVE ADVANCED, RELAPSED OR REFRACTORY SOLID TUMOR OR LYMPHOMA (KEYNOTE-051)

View on source registry